^
3d
Enrollment closed
|
Nubeqa (darolutamide) • saruparib (AZD5305)
8d
Endoplasmic reticulum stress-based ATF6 signaling pathway: evaluation of 4-PBA improving retinal state in myopic guinea pigs. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Retinas in the LIM group showed thinning, disorganized layers, and reduced FERG amplitudes (Cone-b/Rod-b/OPs)...4-PBA mitigates retinal damage in myopia by inhibiting ATF6-mediated ERS, reducing calcium overload, restoring mitochondrial function, and suppressing the ATF6-CHOP-Bax apoptotic cascade. This study identifies the ATF6 pathway as a therapeutic target for myopic retinopathy and supports 4-PBA's potential as a retinal protective agent.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ATF6 (Activating Transcription Factor 6) • ANXA5 (Annexin A5)
|
Akeega (abiraterone/niraparib)
8d
Clinical Characteristics and Development of a Risk-Identification Model for Incidentally Detected Cancer in Patients with Diabetes: A Case-Control Study. (PubMed, Diabetes Metab Syndr Obes)
Model A predictors were age, sex, body mass index, HbA1c, mean glucose, mean amplitude of glycaemic excursions (MAGE) from the first 72 h of capillary glucose, 2-hour C-peptide, apolipoprotein A-I (ApoA-I), albumin, and sodium-glucose cotransporter 2 (SGLT2) inhibitor use...Adding tumour markers, particularly CYFRA21-1, improved discrimination. Prospective multicentre validation and assessment of clinical and economic impact are warranted before implementation.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • KRT19 (Keratin 19) • APOA1 (Apolipoprotein A-I) • CA 19-9 (Cancer antigen 19-9)
|
Akeega (abiraterone/niraparib)
13d
APOE4 and doxorubicin impair inhibitory interneuron function and homeostatic regulation in the entorhinal cortex. (PubMed, PLoS One)
For EC pyramidal neurons, the chemotherapeutic agent doxorubicin caused increases in the amplitudes of both spontaneous excitatory and inhibitory post-synaptic currents, with significant responses (***p < 0.001; **p < 0.01 respectively) in APOE3 brains. Doxorubicin doubled the percentage of PV cells that showed inactivation block in APOE3 brains (25% to 52%) but had no effect on APOE4 brains (50% to 54%). This ex vivo study suggests that APOE4 impairs homeostatic synaptic transmission in pyramidal cells under control conditions and causes a lack of responsiveness to a stressor (doxorubicin treatment) in PV cells.
Journal
|
APOE (Apolipoprotein E)
|
doxorubicin hydrochloride • Akeega (abiraterone/niraparib)
15d
A review of the circadian regulation of stem cells: harnessing the internal body clock for enhanced regenerative therapies. (PubMed, Stem Cell Res Ther)
Circadian oscillators act as temporal gatekeepers of stem-cell function. Mapping the molecular interfaces between clock genes and developmental signaling pathways reveals new opportunities to refine regenerative therapies. Chronotherapeutic strategies, i.e. timing interventions to intrinsic circadian phases may enhance the efficacy, precision, and safety of stem-cell-based treatments.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
Akeega (abiraterone/niraparib)
19d
EIK1003-001: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=156, Recruiting, Eikon Therapeutics | N=70 --> 156 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Feb 2026 --> Jun 2027
Enrollment change • Trial completion date • Trial primary completion date • First-in-human
|
HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
20d
Kidney and brain-expressed protein upregulation in the anterior cingulate cortex mediates chronic post-thoracotomy pain by the phospho-protein kinase Mζ/glutamate receptor 1 signaling pathway and neuroinflammation in male rats. (PubMed, Pain)
Patch-clamp recordings revealed that zeta inhibitory peptide inhibited the amplitude of evoked excitatory postsynaptic currents (EPSCs) and the frequency of miniature EPSCs in CPTP and KIBRA overexpression groups. These results demonstrate that KIBRA in ACC neurons significantly contributes to CPTP by p-PKMζ/GluR1 and neuroinflammation, offering novel mechanistic insights. However, as the study was conducted exclusively in male animals, and studies in clinical settings have shown that the CPTP prevalence is higher among females, the findings primarily apply to males, underscoring the need for future sex-specific investigations.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
Akeega (abiraterone/niraparib)
23d
Acupotomy combined with acupuncture for acute peripheral facial paralysis with mastoid region pain: a randomized controlled trial (PubMed, Zhongguo Zhen Jiu)
Electromyography (EMG) was used to assess latency and amplitude ratios (affected/healthy side) of the frontal, orbicularis oculi, and orbicularis oris muscles...The total effective rate in the observation group was 93.1% (27/29), higher than that in the control group (82.1%, 23/28, P<0.05). Acupotomy combined with acupuncture could promote recovery of facial nerve function and shorten the duration of mastoid region pain in patients with acute peripheral facial paralysis with mastoid region pain.
Clinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
|
Akeega (abiraterone/niraparib)
28d
The Regulation of Vasomotor and Cardiorespiratory Pulsations Is Disrupted in Primary Central Nervous System Lymphoma: A Case-Control fMRI Study. (PubMed, Hum Brain Mapp)
Vasomotor pulsations may arise from amplitude modulations of respiratory (RPE) and cardiovascular (CHE) pulsations while cardiovascular fluctuations may be modulated by respiration through cardiorespiratory amplitude modulation (CREM)...While elevations in all pulsations were present within (peri)tumoral regions, AFRPE elevations extended into extra-tumoral white matter and grey matter. Thus, altered cardiorespiratory fluctuations give rise to dysfunctional vasomotor and CSF pulsations in PCNSL, predicting impaired glymphatic function.
Journal
|
CREM (CAMP Responsive Element Modulator)
|
Akeega (abiraterone/niraparib)
29d
Lactate potentiates NMDA receptor currents via an intracellular redox mechanism targeting GluN2B subunits: implications for synaptic plasticity. (PubMed, J Physiol)
Using patch-clamp recordings in cultured cortical neurons we found that lactate enhances NMDA receptor currents (INMDAR), increasing their amplitude and decay time constant...Lactate strengthens the interaction between CaMKII and GluN2B through redox-sensitive cysteine residues in GluN2B, facilitating synaptic localization of this complex and enhancing synaptic responses. These findings reveal a molecular pathway by which lactate, produced by astrocytes, can significantly influence neuronal activity and synaptic function, linking brain metabolism with learning and memory processes.
Journal
|
MAGEE1 (MAGE family member E1) • GRIN2B (Glutamate Ionotropic Receptor NMDA Type Subunit 2B)
|
Akeega (abiraterone/niraparib)
1m
Discovery of selective PARP1/CDK6 dual target inhibitors modulating Wnt signaling pathway for the treatment of TNBC. (PubMed, Bioorg Chem)
Herein, we report the rational design and synthesis of a series of second-generation selective PARP1/CDK6 dual inhibitors, based on the structural features of the latest selective PARP1 inhibitor AZD5305...Furthermore, compared with first-generation inhibitors, PC8 displays improved metabolic stability in liver microsomes. As a novel selective PARP1/CDK6 dual inhibitor with improved pharmacological properties, PC8 represents a promising lead structure for further optimization of second-generation PARP1/CDK6 dual inhibitors for the treatment of TNBC.
Journal
|
CDK6 (Cyclin-dependent kinase 6) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
|
saruparib (AZD5305)
1m
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (clinicaltrials.gov)
P1, N=41, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Apr 2026 | Trial primary completion date: Jul 2026 --> Feb 2026
Enrollment closed • Trial completion date • Trial primary completion date
|
metformin • saruparib (AZD5305)